Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WHO Recommended Dose of Pralidoxime in Organophosphorus Poisoning
NCT02040350Phase 1Completed
- Sponsor
- Sher-i-Kashmir Institute of Medical Sciences
- Start
- Apr 2012
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in organophosphate poisoning comparing Pralidoxime with Placebo (2 arms). Primary endpoint: Mortality Rate at 1 year. Started Apr 2012; status: completed.
02
Drugs
pralidoxime
03
Conditions
organophosphate poisoning
Beyond the preview
Go deeper on NCT02040350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040350.